Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291306 | 0.84 | CDK2 (0.56) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL4291141 | 0.79 | CDK2 (0.65) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL11339041 | 0.76 | CDK2 (0.58) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL9521763 | 0.76 | PKM (0.70) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL10373441 | 0.76 | PKM (0.59) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL9523984 | 0.75 | PKM (0.62) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL4295974 | 0.74 | CDK2 (0.47) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL4296063 | 0.73 | CDK2 (0.54) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL9776573 | 0.73 | PKM (0.62) | CDK2PKMPOLBCDK1CCNB1 | |
| SCHEMBL9776497 | 0.71 | PKM (0.60) | CDK2PKMPOLBCDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | CDK2 1200/4885PKM 2524/4885POLB 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.